Cargando…
Androgen receptor is a determinant of melanoma targeted drug resistance
Melanoma provides a primary benchmark for targeted drug therapy. Most melanomas with BRAF(V600) mutations regress in response to BRAF/MEK inhibitors (BRAFi/MEKi). However, nearly all relapse within the first two years, and there is a connection between BRAFi/MEKi-resistance and poor response to immu...
Autores principales: | Samarkina, Anastasia, Youssef, Markus Kirolos, Ostano, Paola, Ghosh, Soumitra, Ma, Min, Tassone, Beatrice, Proust, Tatiana, Chiorino, Giovanna, Levesque, Mitchell P., Goruppi, Sandro, Dotto, Gian Paolo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10576812/ https://www.ncbi.nlm.nih.gov/pubmed/37838724 http://dx.doi.org/10.1038/s41467-023-42239-w |
Ejemplares similares
-
HSD17B7 gene in self‐renewal and oncogenicity of keratinocytes from Black versus White populations
por: Xu, Xiaoying, et al.
Publicado: (2021) -
Sustained androgen receptor signaling is a determinant of melanoma cell growth potential and tumorigenesis
por: Ma, Min, et al.
Publicado: (2020) -
Comprehensive Gene Expression Analysis to Identify Differences and Similarities between Sex- and Stage-Stratified Melanoma Samples
por: Chrysanthou, Eirini, et al.
Publicado: (2022) -
Dual tumor suppressing and promoting function of Notch1 signaling in human prostate cancer
por: Lefort, Karine, et al.
Publicado: (2016) -
CSL controls telomere maintenance and genome stability in human dermal fibroblasts
por: Bottoni, Giulia, et al.
Publicado: (2019)